Merck & Company (MRK) 58.81 $MRK
Achillion Pharmaceuticals: High Marketing Potential With Long-Term Prospects
Steven Giardino - at Seeking Alpha - 12 mins ago
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 7.18 (+0.06), MRK: 58.81 (-0.07)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 16.78 (-0.12), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), PEP: 99.13 (-1.14), CELG: 115.88 (+0.16), DPS: 76.95 (-1.35), ZTS: 45.46 (-0.33), HALO: 14.73 (+0.23), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), MRK: 58.81 (-0.07), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), REGN: 402.40 (+0.66)
CORRECTION - Merck: Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
PR Newswire Europe - Fri Feb 13, 2:35AM CST
DARMSTADT, Germany, February 13, 2015 /PRNewswire/ --
MRK: 58.81 (-0.07)
Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
PR Newswire Europe - Fri Feb 13, 12:36AM CST
DARMSTADT, Germany, February 13, 2015 /PRNewswire/ --
MRK: 58.81 (-0.07)
Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:10PM CST
Amgen's (AMGN) experimental skin cancer treatment, talimogene laherparepvec, is scheduled to face twin FDA advisory committees on Apr 29, 2015.
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30)
Novavax starts early stage Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 12:18PM CST
JNJ: 99.62 (+1.18), NVAX: 8.80 (+0.40), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
AbbVie files NDA in Japan for 12-week once-daily HCV combo med
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:25AM CST
GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)
38.69% Edge To 5 Dow, Highest Yield, Lowest Price, February Stocks With Merck
Fredrik Arnold - at Seeking Alpha - Wed Feb 11, 11:48PM CST
T: 34.66 (+0.05), GE: 25.15 (+0.26), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), XOM: 93.37 (+1.00), MCD: 95.65 (+0.56), PG: 85.90 (-0.13), CAT: 85.13 (+1.60), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21)
Elite 10 Dow Dividend Dogs Display 9.72% To 18% Upsides For February
Fredrik Arnold - at Seeking Alpha - Wed Feb 11, 8:40PM CST
GE: 25.15 (+0.26), AXP: 78.08 (-2.40), NKE: 92.04 (+0.04), UNH: 109.44 (-0.40), PFE: 34.64 (-0.23), INTC: 34.36 (+0.23), T: 34.66 (+0.05), JNJ: 99.62 (+1.18), JPM: 59.67 (+0.10), MRK: 58.81 (-0.07), DD: 76.18 (-0.11), MCD: 95.65 (+0.56), PG: 85.90 (-0.13), CAT: 85.13 (+1.60), CVX: 112.78 (+1.92), MSFT: 43.87 (+0.78), VZ: 49.31 (-0.21), CSCO: 29.43 (-0.03)
The Dogs Of The Dow Get Off To A Sluggish Start In 2015
Value Line - Seeking Alpha - Wed Feb 11, 6:30PM CST
By Robert M. Greene The year got off to a slow start for The Dogs of the Dow, as these stocks had limited success overcoming the headwinds in the broader equity markets. In all, an equally-weighted position in the 10-highest yielding Dow stocks at...
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), CAT: 85.13 (+1.60), CVX: 112.78 (+1.92)
Axial Spondyloarthritis - Global Clinical Trials Review 2015
M2 - Wed Feb 11, 2:31PM CST
Research and Markets (http://www.researchandmarkets.com/research/lzmwwt/axial) has announced the addition of the "Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Axial Spondyloarthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Axial Spondyloarthritis. Scope: - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Pfizer Inc. - AbbVie Inc. - UCB Biosciences Inc. - Merck & Co., Inc. - UCB Biosciences GmbH Clinical Trial Overview of Top Institutes / Government - Glostrup University Hospital - Ghent University Hospital - Charite - Universitatsmedizin Berlin - Sociedad Espanola de Farmacologia Clinica - The First Affiliated Hospital of Zhengzhou University - Diakonhjemmet Hospital - Rheumatism Foundation Hospital - Tuen Mun Hospital - University hospital of North Norway - University of Zurich For more information visit http://www.researchandmarkets.com/research/lzmwwt/axial
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Watch for Shares of Merck (MRK) to Approach Support at $58.42
Comtex SmarTrend(R) - Wed Feb 11, 12:28PM CST
Shares of Merck (NYSE:MRK) have bearishly opened below the pivot of $58.99 today and have reached the first support level of $58.63. Should the shares continue to fall, the support pivots of $58.42 and $57.85 will be of interest.
MRK: 58.81 (-0.07)
Comments On Gilead's Quarter And The Road Ahead
DoctoRx - at Seeking Alpha - Wed Feb 11, 11:57AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
FlexEnable and Merck Take Major Step Forward in Plastic LCD Technology
PR Newswire Europe - Wed Feb 11, 5:04AM CST
CAMBRIDGE, England, February 11, 2015 /PRNewswire/ --
MRK: 58.81 (-0.07)
SPDR(R) ETF Family Announces Impact of Receiving Settlement Payment
Business Wire - Tue Feb 10, 4:13PM CST
The SPDR(R) Exchange Traded Funds (ETFs) listed in the table below, announced today that each fund received a payment as an authorized claimant from a class action settlement related to Merck & Co., Inc.
STT: 76.93 (-0.46), MRK: 58.81 (-0.07)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Making The Bull Case For Merck And Applauding Its 'Apple' Priced Debt Offering
Dallas Salazar - at Seeking Alpha - Tue Feb 10, 12:39AM CST
MRK: 58.81 (-0.07)
Achillion Pharmaceuticals: High Marketing Potential With Long-Term Prospects
Steven Giardino - at Seeking Alpha - 12 mins ago
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 7.18 (+0.06), MRK: 58.81 (-0.07)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 16.78 (-0.12), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), PEP: 99.13 (-1.14), CELG: 115.88 (+0.16), DPS: 76.95 (-1.35), ZTS: 45.46 (-0.33), HALO: 14.73 (+0.23), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), MRK: 58.81 (-0.07), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), REGN: 402.40 (+0.66)
CORRECTION - Merck: Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
PR Newswire Europe - Fri Feb 13, 2:35AM CST
DARMSTADT, Germany, February 13, 2015 /PRNewswire/ --
MRK: 58.81 (-0.07)
Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
PR Newswire Europe - Fri Feb 13, 12:36AM CST
DARMSTADT, Germany, February 13, 2015 /PRNewswire/ --
MRK: 58.81 (-0.07)
Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:10PM CST
Amgen's (AMGN) experimental skin cancer treatment, talimogene laherparepvec, is scheduled to face twin FDA advisory committees on Apr 29, 2015.
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30)
Novavax starts early stage Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 12:18PM CST
JNJ: 99.62 (+1.18), NVAX: 8.80 (+0.40), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
AbbVie files NDA in Japan for 12-week once-daily HCV combo med
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:25AM CST
GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)
38.69% Edge To 5 Dow, Highest Yield, Lowest Price, February Stocks With Merck
Fredrik Arnold - at Seeking Alpha - Wed Feb 11, 11:48PM CST
T: 34.66 (+0.05), GE: 25.15 (+0.26), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), XOM: 93.37 (+1.00), MCD: 95.65 (+0.56), PG: 85.90 (-0.13), CAT: 85.13 (+1.60), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21)
Elite 10 Dow Dividend Dogs Display 9.72% To 18% Upsides For February
Fredrik Arnold - at Seeking Alpha - Wed Feb 11, 8:40PM CST
GE: 25.15 (+0.26), AXP: 78.08 (-2.40), NKE: 92.04 (+0.04), UNH: 109.44 (-0.40), PFE: 34.64 (-0.23), INTC: 34.36 (+0.23), T: 34.66 (+0.05), JNJ: 99.62 (+1.18), JPM: 59.67 (+0.10), MRK: 58.81 (-0.07), DD: 76.18 (-0.11), MCD: 95.65 (+0.56), PG: 85.90 (-0.13), CAT: 85.13 (+1.60), CVX: 112.78 (+1.92), MSFT: 43.87 (+0.78), VZ: 49.31 (-0.21), CSCO: 29.43 (-0.03)
The Dogs Of The Dow Get Off To A Sluggish Start In 2015
Value Line - Seeking Alpha - Wed Feb 11, 6:30PM CST
By Robert M. Greene The year got off to a slow start for The Dogs of the Dow, as these stocks had limited success overcoming the headwinds in the broader equity markets. In all, an equally-weighted position in the 10-highest yielding Dow stocks at...
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), CAT: 85.13 (+1.60), CVX: 112.78 (+1.92)
Axial Spondyloarthritis - Global Clinical Trials Review 2015
M2 - Wed Feb 11, 2:31PM CST
Research and Markets (http://www.researchandmarkets.com/research/lzmwwt/axial) has announced the addition of the "Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Axial Spondyloarthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Axial Spondyloarthritis. Scope: - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Pfizer Inc. - AbbVie Inc. - UCB Biosciences Inc. - Merck & Co., Inc. - UCB Biosciences GmbH Clinical Trial Overview of Top Institutes / Government - Glostrup University Hospital - Ghent University Hospital - Charite - Universitatsmedizin Berlin - Sociedad Espanola de Farmacologia Clinica - The First Affiliated Hospital of Zhengzhou University - Diakonhjemmet Hospital - Rheumatism Foundation Hospital - Tuen Mun Hospital - University hospital of North Norway - University of Zurich For more information visit http://www.researchandmarkets.com/research/lzmwwt/axial
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Watch for Shares of Merck (MRK) to Approach Support at $58.42
Comtex SmarTrend(R) - Wed Feb 11, 12:28PM CST
Shares of Merck (NYSE:MRK) have bearishly opened below the pivot of $58.99 today and have reached the first support level of $58.63. Should the shares continue to fall, the support pivots of $58.42 and $57.85 will be of interest.
MRK: 58.81 (-0.07)
Comments On Gilead's Quarter And The Road Ahead
DoctoRx - at Seeking Alpha - Wed Feb 11, 11:57AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
FlexEnable and Merck Take Major Step Forward in Plastic LCD Technology
PR Newswire Europe - Wed Feb 11, 5:04AM CST
CAMBRIDGE, England, February 11, 2015 /PRNewswire/ --
MRK: 58.81 (-0.07)
SPDR(R) ETF Family Announces Impact of Receiving Settlement Payment
Business Wire - Tue Feb 10, 4:13PM CST
The SPDR(R) Exchange Traded Funds (ETFs) listed in the table below, announced today that each fund received a payment as an authorized claimant from a class action settlement related to Merck & Co., Inc.
STT: 76.93 (-0.46), MRK: 58.81 (-0.07)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Making The Bull Case For Merck And Applauding Its 'Apple' Priced Debt Offering
Dallas Salazar - at Seeking Alpha - Tue Feb 10, 12:39AM CST
MRK: 58.81 (-0.07)
